Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging

Trial StartNine-Amino-Acid PeptidePositive

AI Analysis

Summary

Immorta Bio announced an AI-designed nine-amino-acid peptide senolytic immunotherapy targeting diseases of aging, with clinical entry planned for 2026. The therapy is designed to restore the immune system's ability to eliminate senescent cells.

Outcome Details

Clinical entry planned for 2026

Importance:5/10

Sentiment:

0.60

senolyticimmunotherapyagingAI-designedpeptidesenescent cells

Read the original article

Published by PR Newswire Biotech on October 12, 2026 1:22 PM

Read Original